Denosumab treatment is associated with the absence of circulating tumor cells in patients with breast cancer.

We also observed that although HER2 was expressed in 22% (13 of 61) of patients with no CTC clusters (7 of 39) (i.e., 17.95% of patients with no CTCs and 6 of 22 [30%] of patients with single CTCs only), it was expressed in only 1 patient (9.09%) with CTC clusters (OR, 0.36; 95% CI, 0.01–2.97; P = 0.44), even though the relationship between HER2 negativity and CTC clusters did not reach statistical significance (Table 3 ).

also in 111,027 other papers